Targeted Nanocarrier Combination Based Therapy for Lung Cancer

靶向纳米载体组合治疗肺癌

基本信息

批准号：
8355084
负责人：
Mandip Singh Sachdeva
金额：
$ 16.48万
依托单位：
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-16 至 2017-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8355084
关键词：
A549 Adverse effects African American Age Biological Availability Bypass Cancer Center Cancer Patient Cell Line Combination Drug Therapy Community Services Death Rate Dose Drug Formulations Exhibits Frequencies Future Growth Human Incidence Investigation Laboratories Lung Neoplasms Lymphatic Malignant Neoplasms Malignant neoplasm of lung Metabolism Methods Minority Groups Modeling Molecular Non-Small-Cell Lung Carcinoma Noscapine Nude Mice Oral Oral Administration Outcome Pharmaceutical Preparations Platinum Population Research Project Grants Research Training System TdT-Mediated dUTP Nick End Labeling Assay Therapeutic Woman absorption anticancer activity anticancer research base caucasian American chemotherapeutic agent chemotherapy improved in vivo indexing man mannosamine mortality nanocarrier novel novel strategies racial and ethnic research study response tumor tumor growth tumor xenograft

项目摘要

Research Project 1- Targeted Nanocarrier Combination Based Therapy for Lung Cancer - Dr. Mandip Sachdeva: Lung cancer incidence rate in African American is 50% higher than that of white Americans. African Americans have the highest cancer incidence and mortality rates of any racial/ethnic minority group in the U.S. Furthermore, its incidence continues to steadily rise among both African and white American women. The age adjusted death rate among African American population from lung cancer was found to be 12%. The recommended first line of chemotherapy In NSCLC is platinum based combination chemotherapy. Despite recent advances in chemotherapy, response rates in NSCLC remain <50% and also chemotherapy is associated with adverse effects. This necessitates investigation on chemotherapeutic options having potent anticancer activity and lower side effects to improve therapeutic outcomes in treatment of lung cancer. Noscapine (Nos). an antimicrotubular agent, has been shown to have promising anticancer activity. Our laboratory has already demonstrated that oral administration of Nos significantiy regress tumor growth in dose dependent manner in H460 xenograft tumor model. The use of Nos has been limited due to extensive first pass metabolism and poor bioavailability. Therefore, enhancing oral bioavailability of Nos using nanocarrier delivery system which can bypass the first pass effect (coated with mannosamine) and delivering in combination with chemotherapeutic agents to exert synergistic antitumor activity is a novel approach in treatment of lung cancer.

研究项目 1 - 靶向纳米载体组合治疗肺癌 - Dr. Mandip Sachdeva：非裔美国人的肺癌发病率比美国白人高 50%。在美国所有种族/族裔群体中，非裔美国人的癌症发病率和死亡率最高。此外，非洲裔和美国白人女性的癌症发病率持续稳步上升。非裔美国人肺癌的年龄调整死亡率为 12%。 NSCLC 推荐的一线化疗是铂类联合化疗。尽管化疗最近取得了进展，但 NSCLC 的缓解率仍然低于 50%，而且化疗与不良反应相关。这就需要研究具有有效抗癌活性和较低副作用的化疗方案，以改善肺癌的治疗效果。诺斯卡品（Nos）。一种抗微管剂，已被证明具有良好的抗癌活性。我们的实验室已经证明，在H460异种移植肿瘤模型中，口服Nos可以以剂量依赖性方式显着抑制肿瘤生长。由于首过代谢广泛且生物利用度差，Nos 的使用受到限制。因此，利用可绕过首过效应（包被甘露糖胺）的纳米载体递送系统提高Nos的口服生物利用度，并与化疗药物联合递送以发挥协同抗肿瘤活性，是治疗肺癌的一种新方法。